Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Orthofix Medical Inc. is a global medical device company focused on developing, manufacturing, and commercializing orthopedic and spine solutions. The company operates primarily in the orthopedic medical devices and spine surgery industries, serving surgeons and healthcare institutions with products designed to restore mobility, alleviate pain, and improve patient outcomes. Its core offerings address musculoskeletal conditions through fixation systems, biologic solutions, and spinal implant technologies.
The company’s primary revenue drivers are its Global Spine and Bone Growth Therapies segments, which include spinal implants, external fixation systems, bone growth stimulators, and regenerative biologics. Orthofix primarily serves orthopedic surgeons, neurosurgeons, hospitals, and ambulatory surgery centers, with a strategic emphasis on differentiated technologies that address complex clinical needs. Founded in the early 1980s, Orthofix evolved through internal innovation and acquisitions, most notably expanding its spine portfolio through the acquisition of SeaSpine Holdings Corporation in 2023, which significantly reshaped its scale and competitive positioning.
Business Operations
Orthofix operates through two principal business segments: Global Spine and Bone Growth Therapies. The Global Spine segment focuses on spinal fixation and motion-preservation systems, biologics, and procedural solutions used in thoracolumbar, cervical, and complex spine surgeries. The Bone Growth Therapies segment provides non-invasive and implantable bone growth stimulation devices used to enhance healing in spinal fusion and fracture repair procedures.
Operations span both domestic and international markets, with manufacturing, distribution, and sales activities across multiple regions. Orthofix controls proprietary technologies related to spinal implants, biologic materials, and pulsed electromagnetic field stimulation. The company maintains a combination of direct sales forces and distributor relationships and operates through subsidiaries in key markets to support localized regulatory, commercial, and clinical needs.
Strategic Position & Investments
Orthofix’s strategic direction centers on becoming a focused, pure-play spine and orthopedic growth company with a differentiated portfolio addressing both surgical and non-surgical care pathways. A key growth initiative was the acquisition of SeaSpine Holdings Corporation, which expanded Orthofix’s spinal implant portfolio, surgeon relationships, and procedural breadth while creating opportunities for cost synergies and cross-selling.
The company continues to invest in product development, surgeon education, and biologics innovation to strengthen its competitive position. Emerging areas of focus include advanced spinal fixation systems, regenerative orthobiologics, and technologies designed to support minimally invasive and complex spine procedures. These investments align with Orthofix’s strategy to compete in specialized, higher-acuity segments of the orthopedic market rather than commoditized device categories.
Geographic Footprint
Orthofix is headquartered in the United States and maintains a broad international presence across North America, Europe, Latin America, and select Asia-Pacific markets. The company generates a significant portion of its revenue outside the U.S., reflecting its established distribution networks and localized subsidiaries in key international regions.
International operations include sales offices, regulatory support functions, and distributor partnerships that extend Orthofix’s reach into both developed and emerging healthcare markets. This global footprint allows the company to participate in diverse reimbursement environments and surgical practice patterns while balancing regional demand cycles.
Leadership & Governance
Orthofix is led by an executive team with experience across medical devices, orthopedics, and global healthcare operations. The leadership emphasizes operational discipline, portfolio focus, and innovation-driven growth following the company’s strategic transformation and merger activity.
Key executives include:
- Massimo Calafiore – President and Chief Executive Officer
- Kevin Kenny – Chief Financial Officer
- Jason Kraus – Chief Commercial Officer
The leadership team’s strategic vision centers on integrating acquired assets, strengthening surgeon partnerships, and driving sustainable growth through differentiated spine and orthopedic solutions, supported by disciplined governance and compliance with U.S. public company standards.